Stock PHXM PHAXIAM THERAPEUTICS S.A.
Add to a list
To use this feature you must be a member
Log inSign up

Financials PHAXIAM Therapeutics S.A. Euronext Paris

Equities

PHXM

FR0011471135

Biotechnology & Medical Research

Market Closed - Euronext Paris
Other stock markets
 11:35:26 2024-04-26 am EDT 		5-day change 1st Jan Change
2.95 EUR 0.00% Intraday chart for PHAXIAM Therapeutics S.A. +1.03% -35.87%
Apr. 15 Phaxiam initiates trial in infective endocarditis CF
Apr. 15 PHAXIAM Therapeutics Announces Enrolment of First Patient in the Phase 1 Study for the Treatment of Endocarditis Infections Caused by Staphylococcus Aureus CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025
Capitalization 1 120.2 139.1 65.75 11.38 27.94 17.92 -
Enterprise Value (EV) 1 61.09 122.1 57.43 -13.85 27.94 18.37 28.47
P/E ratio -1.92 x -1.78 x -0.93 x -36.7 x - -2.09 x -3.11 x
Yield - - - - - - -
Capitalization / Revenue 22.7 x 37.4 x 15.7 x 0.37 x - 17.1 x 11.2 x
EV / Revenue 11.6 x 32.8 x 13.7 x -0.45 x - 17.5 x 17.8 x
EV / EBITDA -1.02 x -1.91 x -1.12 x -7.59 x - -1.05 x -1.58 x
EV / FCF -0.96 x -2.31 x -1.01 x 0.43 x - 91.9 x 24.8 x
FCF Yield -104% -43.3% -99.4% 230% - 1.09% 4.04%
Price to Book 1.4 x 4.93 x 2.2 x 0.48 x - - -
Nbr of stocks (in thousands) 1,794 1,956 3,102 3,102 6,075 6,075 -
Reference price 2 67.00 71.10 21.20 3.668 4.600 2.950 2.950
Announcement Date 3/16/20 3/8/21 4/27/22 3/22/23 3/20/24 - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025
Net sales 1 5.283 3.718 4.18 31 - 1.05 1.6
EBITDA 1 -59.86 -63.84 -51.14 1.824 - -17.5 -18
EBIT 1 -64.07 -68.83 -56.52 -2.796 -23.66 1 3.55
Operating Margin -1,212.83% -1,851.32% -1,352.03% -9.02% - 95.24% 221.87%
Earnings before Tax (EBT) -62.66 -73.3 -53.8 - - - -
Net income 1 -62.66 -73.3 -53.8 -0.227 -23.49 -0.9 1.05
Net margin -1,186.05% -1,971.49% -1,287.01% -0.73% - -85.71% 65.62%
EPS 2 -34.90 -39.90 -22.70 -0.1000 - -1.410 -0.9500
Free Cash Flow 1 -63.43 -52.86 -57.07 -31.85 - 0.2 1.15
FCF margin -1,200.59% -1,421.71% -1,365.26% -102.75% - 19.05% 71.87%
FCF Conversion (EBITDA) - - - - - - -
FCF Conversion (Net income) - - - - - - 109.52%
Dividend per Share - - - - - - -
Announcement Date 3/16/20 3/8/21 4/27/22 3/22/23 3/20/24 - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2019 S2 2020 S1 2020 S2 2021 S1 2021 Q3 2021 Q4 2022 Q1 2022 S1 2022 Q3
Net sales 1 2.318 1.849 1.869 2.27 1.13 0.96 0.539 - 0.47
EBITDA -30.71 -33.63 -30.98 -26.47 - - - - -
EBIT -33.83 -35.37 -33.46 -28.97 -14.6 -13.77 -12.52 - -
Operating Margin -1,459.4% -1,912.87% -1,790.42% -1,276.04% -1,292.04% -1,434.38% -2,321.89% - -
Earnings before Tax (EBT) -33.38 -34.96 -38.34 -27.95 -13.63 - -11.91 - -
Net income 1 -33.37 -34.96 -38.34 -27.95 -13.63 - -11.91 -1.024 -5.139
Net margin -1,439.73% -1,890.86% -2,051.26% -1,231.37% -1,206.19% - -2,209.83% - -1,093.4%
EPS -18.60 -19.50 -20.40 -12.20 - - - -0.3000 -
Dividend per Share - - - - - - - - -
Announcement Date 3/16/20 9/21/20 3/8/21 9/20/21 11/21/22 4/27/22 5/12/22 9/12/22 11/21/22
1EUR in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025
Net Debt 1 - - - - - 0.45 10.6
Net Cash position 1 59.1 17 8.32 25.2 - - -
Leverage (Debt/EBITDA) - - - - - -0.0257 x -0.5861 x
Free Cash Flow 1 -63.4 -52.9 -57.1 -31.8 - 0.2 1.15
ROE (net income / shareholders' equity) -54.2% -131% - - - - -
ROA (Net income/ Total Assets) - - - - - - -
Assets 1 - - - - - - -
Book Value Per Share 47.70 14.40 9.640 7.570 - - -
Cash Flow per Share 2 -24.10 - - - - 2.700 3.400
Capex 1 20.1 1.14 0.3 - - 0.5 0.5
Capex / Sales 380.79% 30.63% 7.13% - - 47.62% 31.25%
Announcement Date 3/16/20 3/8/21 4/27/22 3/22/23 3/20/24 - -
1EUR in Million2EUR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.95 EUR
Average target price
6.85 EUR
Spread / Average Target
+132.20%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.74B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. PHXM Stock
  4. PHXM Stock
  5. Financials PHAXIAM Therapeutics S.A.